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Porphyromonas gingivalisPseudomonas aeruginosa strains resistant towards all currently available antibiotics are increasingly
encountered, raising the need for new anti-pseudomonal drugs. We therefore conducted a medium-
throughput screen of a small-molecule collection resulting in the identification of the N-alkylated 3,6-
dihalogenocarbazol 1-(sec-butylamino)-3-(3,6-dichloro-9H-carbazol-9-yl)propan-2-ol (MIC = 18.5 lg mL1).
This compound, compound 1, is bacteriostatic towards a broad spectrum of Gram-positive and
Gram-negative pathogens, including P. aeruginosa. Importantly, 1 also eradicates mature biofilms of
P. aeruginosa. 1 displays no cytotoxicity against various human cell types, pointing to its potential for
further development as a novel antibacterial drug.
 2014 Elsevier Ltd. All rights reserved.Pseudomonas aeruginosa is a Gram-negative opportunistic path- development of resistance towards all available classes of
ogen that poses a particular risk to immunosuppressed individuals
and other highly vulnerable patients such as those in intensive care
units.1,2 This pathogen is also the dominant cause of life-threaten-
ing chronic lung infections in cystic fibrosis (CF) patients.3 In
addition to its considerable level of intrinsic resistance towards a
wide variety of antibiotics, P. aeruginosa has a remarkable ability
to acquire additional resistance mechanisms. This has led toantibiotics.4 Alarmingly, the number of new antibiotics in the
pharmaceutical pipeline active against P. aeruginosa is very
limited.2,5 Consequently, there is an urgent need to find new
compounds with anti-pseudomonal activity.
To identify novel anti-pseudomonal compounds, we conducted
a medium-throughput screening of a small compound library com-
prising 23,909 commercially available compounds.6–8 The selection
of compounds was based on (i) chemical diversity, (ii) druglike
properties (Lipinski rule of five compliant), (iii) exclusion of unsta-
ble chemical groups and known toxicophores. All compounds were
purchased from multiple commercial suppliers. Compounds that
caused >90% growth inhibition were selected and retested (fresh
sample), after which the most promising compound, 1-(sec-butyla-
mino)-3-(3,6-dichloro-9H-carbazol-9-yl)propan-2-ol, designated
as compound 1 (Fig. 1), was selected for further characterization.
Figure 1. Schematic structure of compound 1. Compound 1 was purchased from
ChemBridge.
V. Liebens et al. / Bioorg. Med. Chem. Lett. 24 (2014) 5404–5408 54051 contains a carbazole motif, which is found in many pharmacolog-
ically important products. Besides antibacterial activity,9–11 a vari-
ety of carbazole derivatives have been reported with antiviral,12,13
antifungal,14,15 anticancer,16–18 anti-inflammatory,19 antimalar-
ial,20,21 antidiarrhoeal,22 mosquitocidal,23 immunosuppressive24
and neuroprotective25 activities.
Commercially available chemical analogues of 1 were selected
and purchased (compounds 2–8, Fig. 2). The minimal inhibitory
concentration (MIC) of these compounds was determined against
P. aeruginosa grown in 1:20 Tryptic Soy Broth (TSB) (Table 2) as
described previously.26 The lowest compound concentration
resulting in the absence of bacterial growth was considered as
the MIC. None of the tested analogs showed better antibacterial
activity against P. aeruginosa compared to the original hit com-
pound 1 (MIC of 18.5 lg mL1, Fig. A.1). The minimal bactericidal
concentration (MBC, concentration resulting in absence of bacterial
regrowth after dilution in Mueller-Hinton Broth (MHB)) of 1
against P. aeruginosa is 18.5 lg mL1, indicating that this com-
pound acts bactericidal. The MIC of 1 against a P. aeruginosa efflux
mutant YM64 lacking all four major mex operons for multidrug
efflux pumps27 is 4.63 lg mL1, which is significantly lower com-
pared to its corresponding wild-type strain YM (MIC of
18.5 lg mL1) (Table 1). This result indicates that 1 probably has
to cross the P. aeruginosa outer membrane to exert its action.
The susceptibility of several clinical isolates obtained from CF
and non-CF patients towards 1 was tested. These strains were as
susceptible towards 1 as the wild-type strain used in our study
(Table 3). In addition, isolates resistant towards specific clinically
used antibiotics did not show cross-resistance towards 1. These
results indicate that 1 is active against strains adapted to in vivo
conditions, including antibiotic treatment regimes.Figure 2. Schematic structure of N-alkylated 3,6-dihalogenocarbazoles represented by nu
5, 6, 7 and 8 from ChemBridge.In vivo, P. aeruginosa is well known to form biofilms, multicellu-
lar structures of cells embedded in a self-produced extracellular
matrix.28,29 The bacterial cells residing in these biofilms are signif-
icantly less susceptible to antibiotics and host defenses. This com-
plicates treatment and often leads to chronic and recurrent
infections.29,30 We assessed whether 1 is capable of preventing bio-
film formation in vitro. The minimal biofilm inhibitory concentra-
tion (MBIC, concentration with 100% biofilm inhibition) was
determined against biofilms grown on polystyrene pegs using the
Calgary biofilm device (Nunc-Immuno TSP, VWR International).31
The results show that 1 completely prevents biofilm formation of
P. aeruginosa at 18.5 lg mL1 (Table 4). To further evaluate the
effect of 1 on biofilm formation on clinically relevant implant
material, the formation of P. aeruginosa biofilms on smooth tita-
nium discs (10 mm diameter, 2 mm thick) in the presence of 1
was investigated.32 The results show that 1 is capable of preventing
biofilm formation of P. aeruginosa, at a concentration as low as
3.7 lg mL1. The total area fraction, defined as the percentage of
surface covered by bacteria, was reduced by approximately 50%
upon addition of 1. Biofilms formed on titanium discs in the pres-
ence of 1 comprised a greater proportion of dead cells within the
biofilm compared to the control experiment. This was most evi-
dent at the highest concentration of 1 (12 lg mL1) (Figs. 3 and
A.2). Taken together, these microscopy results clearly show that
1 prevents biofilm formation of P. aeruginosa on titanium discs.
Next, we tested the capability of 1 to eradicate mature biofilms
of P. aeruginosa grown on polystyrene pegs using the Calgary bio-
film device.31 Treatment of biofilms with 4.63 lg mL1 or higher
concentrations of 1 resulted in a drastic decrease of culturable cells
within the biofilm, which demonstrates the capability of 1 to erad-
icate established biofilms (Fig. 4).
The effect of 1 was subsequently evaluated on the inhibition of
growth26 and biofilm formation31 of other clinically relevant bacte-
ria listed in Table 1. Escherichia coli, Staphylococcus aureus and
Staphylococcus epidermidis were selected as they are frequently
involved in biofilm-associated infections.29 Additionally, the effi-
cacy of 1 was evaluated on the obligate anaerobic pathogen Por-
phyromonas gingivalis, which plays an important role in the
initiation of periodontitis, a biofilm-associated infection of the
gum eventually leading to tooth loss.33 Results shown in Table 4
indicate that 1 is capable of inhibiting both planktonic and biofilm
growth of other clinically important Gram-negative bacteria such
as E. coli and P. gingivalis at concentrations well below those active
against P. aeruginosa. 1 is as potent as the reference antibiotic
chlorhexidine (MIC = 4 lg mL1) against P. gingivalis, but displays
lower activity than ofloxacin (MIC = 0.1 lg mL1) on E. coli. Fur-
thermore, 1 has a bacteriostatic and biofilm inhibitory effect onmbers 2–8. Compounds 2, 3 and 4were purchased from Interbioscreen, compounds
Figure 4. Compound 1 eradicates P. aeruginosa biofilms. 24 h old biofilms of P.
aeruginosa were subjected to a 24 h treatment with different concentrations of 1.
Subsequently, biofilm cells were disrupted by sonication, diluted and plated out
after which the number of surviving cells was determined. This experiment was
repeated independently 3 times, error bars represent standard error of the mean
(SEM). ⁄P <0.05 and ⁄⁄P <0.005.
Figure 3. Representative CLSM micrographs of P. aeruginosa treated with 1. The
extent of the titanium surface that is covered by bacteria in a thin optical section at
full width half maximum is shown after treatment with 0 and 12 lg mL1 of 1. Live
cells were stained with CYTO9 (green) and dead cells were stained with propidium
iodide (red). Scale bar = 5 lm. Each sample was analyzed in triplicate.
Table 1
Bacterial strains
Strain Descriptiona Source or
reference
P. aeruginosa PA14 Wild type, KmR Lee et al.38
P. aeruginosa YM Wild type Morita et al.27
P. aeruginosa YM64 mexAB-oprM::FRT, mexXY::FRT,
mexCD-oprJ::FRT, mexEF-oprN::FRT
Morita et al.27
E. coli TG1 Wild type, [F0 traD36 proAB lacZ
DM15] supE thi-1 D(lac-proAB)
D(mcrB-hsdSM)5(rK - mK -
Carter et al.39
S. aureus SH1000 Functional rsbU derivative of 8325-4
rsbU+ (wild type strain cured of
prophages)
O’Neill40;
Horsburgh
et al.41
S. epidermidis
RP62A
Wild type, ATCC 35984 ATCC
P. gingivalis Wild type, ATCC 33277 ATCC
a KmR: kanamycin resistant.
Table 3
Minimal inhibitory concentration (MIC) of 1 on P. aeruginosa clinical isolates obtained
from cystic fibrosis (CF) and non-CF patients
Clinical isolate Resistance profile MIC 1 (lg mL1)
Non-CF isolates
PA08 Ticarcillin 18.5–37
PA53 Ticarcillin 18.5
PA129 Piperacillin 18.5–37
PA346 Ticarcillin, piperacillin 18.5–37
PA424 Ticarcillin 18.5–37
CF-isolates
PA1250 Ticarcillin, cefepime 18.5
PA1255 Ticarcillin, piperacillin,
ceftazidime, cefepime
18.5–37
PA1256 / 9.25–18.5
PA1270 / 18.5
PA1271 Ticarcillin 18.5–37
Table 2
Minimal inhibitory concentration (MIC) of
N-alkylated 3,6-dihalogenocarbazoles against
P. aeruginosa
Compound MIC (lg mL1)
1 18.5
2 18.5–37
3 >74
4 18.5–37
5 37–148
6 18.5–74
7 74–148
8 18.5–37
Table 4
Minimal inhibitory concentration (MIC) and minimal biofilm inhibitory concentration
(MBIC) of 1 against P. aeruginosa, E. coli, S. aureus, S. epidermidis and P. gingivalis strains
Strain MIC 1
(lg mL1)
MBIC 1
(lg mL1)
Growth
medium
P. aeruginosa PA14 18.5 18.5 1:20 TSB
E. coli TG1 4.63 2.22a 1:20 TSB
S. aureus SH1000 9.25 9.25 MHB
S. epidermidis RP62A 9.25 9.25 MHB
P. gingivalis ATCC 33277 4.63 5.11 1:20 TSB
a MBIC90.
5406 V. Liebens et al. / Bioorg. Med. Chem. Lett. 24 (2014) 5404–5408both Gram-positive S. aureus and S. epidermidis strains. 1 shows
comparable activity with the reference antibiotics ciprofloxacin
(MIC = 6.25 lg mL1) and gentamicin (MIC = 12.5 lg mL1) against
S. aureus. S. epidermidis is more susceptible to ciprofloxacin
(MIC = 1.56 lg mL1) compared to treatment with 1. The capabilityof 1 to target a wide range of bacterial species makes it a promising
starting point for the development of a novel broad-spectrum anti-
biotic. Broad-spectrum agents are of particular importance in the
treatment of acute life-threatening infections where immediate
action is required and identification of the disease-causing patho-
gen is not feasible34 or in case of polymicrobial infections.35 A pos-
sible disadvantage of such a broad-spectrum agent is the higher
chance of resistance development compared to narrow-spectrum
compounds.34 A previous, unrelated screening campaign identified
1 as a candidate antifungal.15 Growth-inhibiting activity against
bacterial as well as fungal pathogens could indicate that 1 targets
an essential cellular process that is conserved among both prokary-
otic and eukaryotic microbes.
As limited human cellular toxicity is an important feature for a
compound with such a broad spectrum of action, the toxicity of 1
was evaluated on several human cell types. Cytotoxicity of 1 was
tested on monolayer cultures of human osteoblasts, mesenchymal
stem cells and endothelial cells, employing standard procedures as
described previously.36 While 2 h of exposure to 4.63 lg mL1 of 1
results in >80% viability for osteoblasts and mesenchymal stem
cells, these conditions are lethal to microvascular endothelial cells
(data not shown). However, the tube formation potential of aortic
endothelial cells is not negatively affected (Figs. 5 and A.3), indicat-
ing that more differentiated endothelial cells in the tube-assem-
bled stage are less susceptible to the potential toxic effects of 1
compared to endothelial cells in the non-assembled stage in
monolayer culture. The observed difference could also be due to
the use of different types of endothelial cells in the two assays,
Figure 5. Tube formation potential of endothelial cells is not affected by 1. Human endothelial cells were cultured in M200 medium with low serum growth supplement
(ENDO) in the presence of 0.5% DMSO (control treatment), 0.05% phenol (positive cytotoxic control) or 4.63 lg mL1 of 1 for 4 h. Average tube length is not inhibited by 1,
whereas 0.05% phenol causes a negative effect on tube formation (P <0.05).
V. Liebens et al. / Bioorg. Med. Chem. Lett. 24 (2014) 5404–5408 5407as endothelial cells from different sources are functionally different
and could therefore behave differently. Moreover, various carbaz-
oles have previously been shown to possess low cellular toxicity
at 80–100 lM,37 pointing to the possibility to further develop 1
into a non-toxic novel antipseudomonal biofilm drug and a
broad-spectrum antibacterial and antifungal agent.
In summary, we here demonstrate that a non-toxic dic-
hlorocarbazol derivative displays anti-pseudomonal activity both
on planktonic and biofilm cultures. Furthermore, 1 inhibits growth
of several other clinically important pathogens making 1 an inter-
esting starting point for the development of a broad-spectrum
antimicrobial agent.
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